datalicense

All datasets / xpertsystems

xpertsystems/hconc009-sample

10 downloads in 30 days0 likesLast modified 26 May 2026View on Hugging Face
Use restrictions

The declared licence (cc-by-nc-4.0) is classified as having use restrictions.

Declared licence
cc-by-nc-4.0, from the tagEvidence: README.md at 47fb234
Licence files
No licence file at the top level of the repositoryEvidence: file list at 47fb234
Declared sources
None listed in the card metadata
Access gated on Hugging Face
No
xpertsystems/hconc009-samplexpertsystems/hconc0…cc-by-nc-4.0: declared licencecc-by-nc-4.0declared licenceREADME.md ↗no licence file: found at top levelno licence fi…found at top levelfile list ↗
xpertsystems/hconc009-samplexpertsystems/hc…cc-by-nc-4.0: declared licencecc-by-nc-4.0declared licenceREADME.md ↗no licence file: found at top levelno licence fi…found at top levelfile list ↗
Each cell links to what was checked: a file, a file list or a Hub record.

Tasks

Citation text from the card

@dataset{xpertsystems_hconc009_2026,
  title  = {HC-ONC-009: Melanoma Synthetic Cohort with AJCC 8th Edition Staging, BRAF/NRAS/KIT/GNAQ Genomic Profiling, KEYNOTE-006 / CheckMate-067 / RELATIVITY-047 Immunotherapy, COMBI-d/v Targeted Therapy, and Organ-Specific Metastasis Tropism},
  author = {{XpertSystems.ai}},
  year   = {2026},
  version= {1.0.0},
  url    = {https://huggingface.co/datasets/xpertsystems/hconc009-sample},
  license= {CC-BY-NC-4.0 (sample); Commercial (full product)},
  note   = {Calibrated against KEYNOTE-006 (Robert 2015, Schachter 2017 pembrolizumab), CheckMate 067 (Larkin 2015, Wolchok 2022 ipilimumab+nivolumab), RELATIVITY-047 (Tawbi 2022 relatlimab+nivolumab anti-LAG3), COMBI-d (Long 2014 dabrafenib+trametinib), COMBI-v (Robert 2015), COLUMBUS (Dummer 2018 encorafenib+binimetinib), coBRIM (Larkin 2014 vemurafenib+cobimetinib), DREAMseq EA6134 (Atkins 2023 sequencing in BRAF+ Stage IV), AJCC 8th Edition Melanoma Staging (Gershenwald 2017), MSLT-II (Faries 2017 SLNB CLND), SEER 2015-2019 incidence/staging, Davies 2002 (BRAF in melanoma), Hodis 2012 (TCGA melanoma genomics), Van Raamsdonk 2009 (GNAQ in uveal), Curtin 2006 (KIT in acral), Hayward 2017 (cutaneous melanoma TMB), Champiat 2017 (hyperprogression on ICI), Lifileucel TIL therapy 2024 FDA approval.}
}

All datasets marked Use restrictions | JSON

The same facts for your agent

A free MCP server at mcp.datalicense.uk/mcp. Connect it from an MCP client such as Claude or Cursor.

dataset_licence({ "id": "xpertsystems/hconc009-sample" })
signal: "restrictive"
stated_licence: "cc-by-nc-4.0"
sources: 0